Il-2 mutant and application thereof
AssigneeShandong Simcere Biopharmaceutical Co., Ltd.
InventorsYingying HU, Zhuoxiao CAO, Renhong TANG, Hu GE, Yayuan FU, Jinsheng REN
Life of this patent
Estimating the term…
Loading patent…
AssigneeShandong Simcere Biopharmaceutical Co., Ltd.
InventorsYingying HU, Zhuoxiao CAO, Renhong TANG, Hu GE, Yayuan FU, Jinsheng REN
Estimating the term…
The present disclosure discloses IL-2 mutants and uses thereof. More specifically, the disclosure provides IL-2 mutants and corresponding fusion proteins, conjugates, nucleic acid fragments, vectors, host cells, methods for preparing the mutants or fusion proteins, IL-2 mutants or fusion proteins prepared according to the methods, pharmaceutical compositions, pharmaceutical uses, methods for treating diseases, and methods for preferentially stimulating regulatory T cells. Compared to wild-type IL-2, the IL-2 mutants of the present disclosure have higher Tm values and improved stability; alternatively, the IL-2 mutants of the present disclosure have an increased yield or changed binding activity to the IL-2Rβγ complexes compared to wild-type IL-2.
An IL-2 mutant comprising one or more mutation(s) at Q13, L18, G27, Y31, A73, H79, P82, I89, N90, V91, V93, F117 or R120 compared to wild-type IL-2.
An IL-2 mutant comprising one or more mutation(s) at H16, D20 or V91 compared to wild-type IL-2;
Dependencies are inferred from the claim text.